What is Zacks Research’s Forecast for Revvity Q3 Earnings?

Revvity, Inc. (NYSE:RVTY) – Equities researchers at Zacks Research cut their Q3 2024 earnings per share (EPS) estimates for shares of Revvity in a research note issued to investors on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.12 per share for the quarter, down from their previous forecast of $1.13. The consensus estimate for Revvity’s current full-year earnings is $4.75 per share. Zacks Research also issued estimates for Revvity’s Q2 2025 earnings at $1.27 EPS, Q3 2025 earnings at $1.29 EPS, FY2025 earnings at $5.15 EPS, Q2 2026 earnings at $1.39 EPS and FY2026 earnings at $5.65 EPS.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. During the same quarter last year, the firm earned $1.21 earnings per share. The firm’s quarterly revenue was down 2.5% compared to the same quarter last year.

A number of other analysts have also issued reports on RVTY. Leerink Partnrs raised Revvity to a “strong-buy” rating in a research report on Monday, July 8th. JPMorgan Chase & Co. increased their target price on Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 30th. Bank of America raised their target price on Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a report on Tuesday, July 30th. TD Cowen boosted their price target on shares of Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Finally, Wells Fargo & Company initiated coverage on shares of Revvity in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $127.20.

Revvity Stock Up 0.2 %

Shares of NYSE:RVTY opened at $116.33 on Thursday. The company has a market capitalization of $14.35 billion, a price-to-earnings ratio of 96.14, a PEG ratio of 3.35 and a beta of 1.05. Revvity has a 12-month low of $79.50 and a 12-month high of $128.15. The business has a 50-day moving average price of $121.51 and a 200 day moving average price of $113.49. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40.

Institutional Trading of Revvity

Hedge funds have recently made changes to their positions in the company. Rothschild Investment LLC purchased a new stake in shares of Revvity in the second quarter valued at approximately $25,000. EverSource Wealth Advisors LLC lifted its holdings in Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after acquiring an additional 167 shares during the period. Fairfield Financial Advisors LTD purchased a new stake in shares of Revvity during the 2nd quarter worth $43,000. Family Firm Inc. acquired a new position in shares of Revvity during the 2nd quarter worth $43,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Revvity in the 1st quarter valued at about $48,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Insider Activity at Revvity

In other news, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the sale, the insider now owns 23,960 shares in the company, valued at approximately $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Tajinder S. Vohra sold 2,153 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $122.09, for a total value of $262,859.77. Following the transaction, the insider now owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joel S. Goldberg sold 3,500 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total value of $412,510.00. Following the sale, the insider now directly owns 33,400 shares of the company’s stock, valued at approximately $3,936,524. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,807 shares of company stock worth $937,576 in the last 90 days. 0.60% of the stock is owned by insiders.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. Revvity’s payout ratio is 23.14%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.